Klin Onkol 2006; 19(2): 143-146.
SUMMARY
Backgrounds: Lysophosphatidic acid (LPA, 1-acyl-2-lyso-sn-glycero-3-phosphate) has been shown to stimulate proliferation of ovarian cancer cells. Elevated LPA levels were detected in early-stage ovarian cancer.
Design and subjects: The objective of this study was to compare plasma lysophosphatidic acid levels in ovarian cancer patients and patients without this disease.
Methods and results: The method for LPA level analysis with specification by capillary electrophoresis using indirect ultraviolet detection has been implemented. Since beginning of this project venous blood samples from 93 patients (29 patients with ovarian cancer, 64 patients without ovarian cancer) have been obtained. Plasma LPA levels were elevated in ovarian cancer patients
(LPA med 19,9 µmol/l, range 4,5 42,7 µmol/l, p<0, 001). Patients without ovarian pathology (n=35) (LPA med 2,6 µmol/l, min 0,9 µmol/l, max 22,9 µmol/l, p<0,001) and patients with benign ovarian disease (n=20) (LPA med 10,4 µmol/l, min 1,1 µmol/l, max 28,8 µmol/l, p<0,001) had statistically significant lower plasma LPA levels compared with ovarian cancer patients.
Conclusions: Our preliminary results suggest that plasma LPA level may represent a potential ovarian cancer marker.
